Toward a more precise future for oncology Editorial
| Authors: | Murciano-Goroff, Y. R.; Taylor, B. S.; Hyman, D. M.; Schram, A. M. |
| Title: | Toward a more precise future for oncology |
| Abstract: | Prospective molecular characterization of cancer has enabled physicians to define the genomic changes of each patient's tumor in real time and select personalized therapies based on these detailed portraits. Despite the promise of such an approach, previously unrecognized biological and therapeutic complexity is emerging. Here, we synthesize lessons learned and discuss the steps required to extend the benefits of genome-driven oncology, including proposing strategies for improved drug design, more nuanced patient selection, and optimized use of available therapies. Finally, we suggest ways that next-generation genome-driven clinical trials can evolve to accelerate our understanding of cancer biology and improve patient outcomes. © 2020 Elsevier Inc. Prospective molecular characterization of cancer has enabled physicians to define the genomic changes of each patient's tumor in real time and select personalized therapies based on these detailed portraits. Despite the promise of such an approach, previously unrecognized biological and therapeutic complexity is emerging. Here, we synthesize lessons learned and discuss the steps required to extend the benefits of genome-driven oncology, including proposing strategies for improved drug design, more nuanced patient selection, and optimized use of available therapies. Finally, we suggest ways that next-generation genome-driven clinical trials can evolve to accelerate our understanding of cancer biology and improve patient outcomes. © 2020 Elsevier Inc. |
| Keywords: | review; patient selection; drug targeting; cancer adjuvant therapy; neoadjuvant therapy; antineoplastic agent; protein degradation; protein; patient monitoring; drug development; drug selectivity; oncology; histology; cancer resistance; chimera; cancer genetics; genome; protein folding; allosterism; futurology; clinical trial design; therapeutic index; time to treatment; human; priority journal; precision oncology; genome-driven oncology; malignant neoplasm; antibody drug conjugate |
| Journal Title: | Cancer Cell |
| Volume: | 37 |
| Issue: | 4 |
| ISSN: | 1535-6108 |
| Publisher: | Cell Press |
| Date Published: | 2020-04-13 |
| Start Page: | 431 |
| End Page: | 442 |
| Language: | English |
| DOI: | 10.1016/j.ccell.2020.03.014 |
| PUBMED: | 32289268 |
| PROVIDER: | scopus |
| PMCID: | PMC7499397 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work